|
|
|
 |
| Location: Home -
Products - Active Pharma Ingredients(API) - Peptide APIs
|
Octreotide acetate
| Catalogue No. : |
C13952 |
| Product Name: |
Octreotide acetate |
| Synonym: |
SMS 201995;Sandostatin;SMS 201-995ac;Sandostatin LAR;CCRIS 8708;SMS 201-995 |
| Chemical Name: |
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2-7)-Disulfide Acetate |
| CAS No. : |
83150-76-9 |
| Structure : |
|
| Molecular Formula: |
C51H70N10O12S2 |
| Molecular Weight: |
1079.29 |
| Purity: |
>98% |
| Usage: |
Octreotide acetate is a long-acting octapeptide with pharmacologic actions mimicking those of the natural hormone somatostatin. Octreotide acetate is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. Octreotide acetate was approved as an injectable depot formulation for the treatment of acromegaly, gigantism, thyrotropinoma, diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in patients with vasoactive intestinal peptide-secreting tumors. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
